Enterprise Value

454.1M

Cash

0.00

Avg Qtr Burn

N/A

Short % of Float

0.03%

Insider Ownership

0.00%

Institutional Own.

3.57%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

PDUFA

Approval decision

Setanaxib (NOX1/NOX4 inhibitor) Details
Primary biliary cholangitis, Liver disease

Phase 2/3

Data readout

Setanaxib (NOX1/NOX4 inhibitor) Details
Solid tumor/s, Cancer, Head and neck squamous cell carcinoma

Phase 2

Data readout

Phase 2

Initiation